cT1-2 N0乳腺癌行乳房切除术后前哨淋巴结活检阳性时腋窝治疗降阶梯:全国登记研究(BOOG 2013-07)
该登记研究纳入2013-2014年荷兰癌症登记中1090例单侧cT1-2 N0乳腺癌行乳房切除术且前哨淋巴结有1-3枚转移(pN1mi-pN1a)的患者,按腋窝处理方式分组。总体5年区域复发率为1.3%,各组间无显著差异;未完成腋窝治疗组5年总生存显著更差,因非癌死亡比例更高。
要点
- 乳房切除术后前哨淋巴结1-3枚转移患者中,未完成腋窝治疗组5年区域复发率与完成腋窝治疗组无显著差异。
- 总体5年区域复发率为1.3%,无复发生存期在各组间相当。
- 未完成腋窝治疗组5年总生存显著更差,归因于非癌死亡比例更高。
核心结论
- 在cT1-2 N0乳腺癌行乳房切除术且前哨淋巴结低体积转移的患者中,5年区域复发率低,且完成与未完成腋窝治疗的患者间相当。
研究设计与样本
- 全国登记研究,纳入2013-2014年荷兰癌症登记中单侧cT1-2 N0乳腺癌行乳房切除术且前哨淋巴结1-3枚转移(pN1mi-pN1a)的女性1090例。
- 按腋窝治疗分为四组:未完成腋窝治疗219例(20.1%)、完成腋窝淋巴结清扫437例(40.1%)、区域放疗327例(30.0%)、完成腋窝淋巴结清扫后区域放疗107例(9.8%)。
- 主要终点为5年区域复发率,次要终点包括无复发生存期和总生存等。
主要发现
- 总体5年区域复发率为1.3%,各组间无显著差异。
- 无复发生存期在各组间相当。
- 未完成腋窝治疗组5年总生存显著更差,因非癌死亡比例更高。
- 未完成腋窝治疗组患者肿瘤特征更有利且年龄更大。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Trials have demonstrated the safety of omitting completion axillary lymph node dissection in patients with cT1-2 N0 breast cancer operated with breast-conserving surgery who have limited metastatic burden in the sentinel lymph node. The aim of this registry study was to provide insight into the oncological safety of omitting completion axillary treatment in patients operated with mastectomy who have limited-volume sentinel lymph node metastasis. METHODS: Women diagnosed in 2013-2014 with unilateral cT1-2 N0 breast cancer treated with mastectomy, with one to three sentinel lymph node metastases (pN1mi-pN1a), were identified from the Netherlands Cancer Registry, and classified by axillary treatment: no completion axillary treatment, completion axillary lymph node dissection, regional radiotherapy, or completion axillary lymph node dissection followed by regional radiotherapy. The primary endpoint was 5-year regional recurrence rate. Secondary endpoints included recurrence-free interval and overall survival, among others. RESULTS: In total, 1090 patients were included (no completion axillary treatment, 219 (20.1%); completion axillary lymph node dissection, 437 (40.1%); regional radiotherapy, 327 (30.0%); completion axillary lymph node dissection and regional radiotherapy, 107 (9.8%)). Patients in the group without completion axillary treatment had more favourable tumour characteristics and were older. The overall 5-year regional recurrence rate was 1.3%, and did not differ significantly between the groups. The recurrence-free interval was also comparable among groups. The group of patients who did not undergo completion axillary treatment had statistically significantly worse 5-year overall survival, owing to a higher percentage of non-cancer deaths. CONCLUSION: In this registry study of patients with cT1-2 N0 breast cancer treated with mastectomy, with low-volume sentinel lymph node metastasis, the 5-year regional recurrence rate was low and comparable between patients with and without completion axillary treatment.
引用
- de Wild SR, van Roozendaal LM, de Wilt JHW, et al. De-escalation of axillary treatment in the event of a positive sentinel lymph node biopsy in cT1-2 N0 breast cancer treated with mastectomy: nationwide registry study (BOOG 2013-07). Br J Surg. 2024. PMID: 38597154. doi:10.1093/bjs/znae077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。